CTXR
Citius Pharmaceuticals Inc.
$1.58
+$0.01(+0.64%)
48
Overall
60
Value
58
Tech
26
Quality
Market Cap
$26.37M
Volume
402.32K
52W Range
$0.65 - $12.85
Target Price
$6.00
Order:
Income Statement
| Metric | Trend | Chart | 2015 Sep | 2016 Sep | 2017 Sep | 2018 Sep | 2019 Sep | 2020 Sep | 2021 Sep | 2022 Sep | 2023 Sep | 2024 Sep |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||||||
| Total Revenue | -- | -- | -- | $818.3K | $90.0K | $90.0K | $90.0K | $90.0K | -- | -- | ||
| Total Revenue | -- | -- | -- | $818.3K | $90.0K | $90.0K | $90.0K | $90.0K | -- | -- | ||
| COST OF GOODS SOLD | ||||||||||||
| Cost of Revenue | -- | -- | $50.0K | $-75.0K | -- | -- | -- | -- | -- | -- | ||
| GROSS PROFIT | ||||||||||||
| Gross Profit | -- | $-45.0K | $-50.0K | $818.3K | $90.0K | $90.0K | $90.0K | $90.0K | -- | -- | ||
| OPERATING EXPENSES | ||||||||||||
| Operating Expenses | $3.5M | $7.4M | $10.0M | $13.8M | $15.6M | $17.7M | $23.5M | $33.3M | $36.7M | $42.0M | ||
| Research & Development | $1.8M | $2.9M | $2.9M | $6.6M | $8.6M | $8.8M | $12.2M | $17.7M | $14.8M | $11.9M | ||
| Research Expense | $1.8M | $2.9M | $2.9M | $6.6M | $8.6M | $8.8M | $12.2M | $17.7M | $14.8M | $11.9M | ||
| Selling, General & Administrative | $946.6K | $3.8M | $6.1M | $6.4M | $6.3M | $8.1M | $9.8M | $11.8M | $15.3M | $18.2M | ||
| General & Administrative Expenses | $946.6K | $3.8M | $6.1M | $6.4M | $6.3M | $8.1M | $9.8M | $11.8M | $15.3M | $18.2M | ||
| Salaries & Wages | $732.2K | $732.2K | $986.6K | $779.7K | $716.0K | $803.3K | $1.5M | $3.9M | $6.6M | $11.8M | ||
| Depreciation & Amortization | -- | $1.3K | $2.6K | -- | -- | -- | -- | -- | -- | -- | ||
| Depreciation & Amortization | -- | -- | $2.6K | -- | -- | -- | -- | -- | -- | -- | ||
| Amortization | -- | $1.6M | $1.6M | $-833.3K | -- | $9.3M | -- | -- | -- | -- | ||
| Other Operating Expenses | -- | -- | -- | -- | -- | $228.8K | $239.0K | $239.6K | $243.6K | $17.3M | ||
| OPERATING INCOME | ||||||||||||
| Operating income | $-3.5M | $-7.4M | $-10.0M | $-13.0M | $-15.6M | $-17.7M | $-23.5M | $-33.3M | $-36.7M | $-42.0M | ||
| EBITDA | $-3.1M | $-8.3M | $-9.5M | $-12.5M | $-15.5M | $-17.4M | $-22.9M | $-33.1M | $-32.9M | $-39.7M | ||
| NON-OPERATING ITEMS | ||||||||||||
| Interest Expense (Non-Operating) | $4.4K | $9.0K | $850.8K | $15.8K | $16.4K | $15.7K | $10.8K | -- | -- | -- | ||
| Intinc | -- | $806 | -- | -- | $52.7K | $68.1K | $261.8K | $251.4K | $1.2M | $758.0K | ||
| Net Non-Operating Interest Income/Expense | $-4.4K | $-8.2K | $-850.8K | $-15.8K | $36.2K | $52.4K | $251.0K | $251.4K | $1.2M | $758.0K | ||
| Gain on Sale of Securities | $-332.1K | -- | -- | -- | -- | -- | $-1.5M | -- | -- | -- | ||
| Other Income/Expense | $-332.1K | $838.2K | $-452.1K | $-450.0K | -- | $-110.2K | $1.2M | -- | $-3.6M | $-2.4M | ||
| Other Special Charges | $768.4K | -- | $1.6M | $450.0K | -- | $110.2K | $226.5K | -- | $3.6M | $2.4M | ||
| SPECIAL ITEMS | ||||||||||||
| Restructring And Mn A Income | $6.6M | -- | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Special Income Charges | $-6.6M | $-11.5M | -- | -- | -- | -- | -- | -- | -- | -- | ||
| PRE-TAX INCOME | ||||||||||||
| EBIT | $-3.1M | $-8.3M | $-9.5M | $-12.5M | $-15.5M | $-17.5M | $-23.0M | $-33.3M | $-33.1M | $-39.9M | ||
| Pre-Tax Income | $-3.1M | $-8.3M | $-10.4M | $-12.5M | $-15.6M | $-17.5M | $-23.1M | $-33.1M | $-32.0M | $-38.8M | ||
| INCOME TAX | ||||||||||||
| Tax Provision | -- | -- | -- | -- | -- | $741 | $1.2K | $576.0K | $576.0K | $576.0K | ||
| NET INCOME | ||||||||||||
| Net Income | $-3.1M | $-8.3M | $-10.4M | $-12.5M | $-15.6M | $-17.5M | $-23.1M | $-33.6M | $-33.7M | $-40.2M | ||
| Net Income (Continuing Operations) | $-3.1M | $-8.3M | $-10.4M | $-12.5M | $-15.6M | $-17.5M | $-23.1M | $-33.6M | $-33.7M | $-40.5M | ||
| Net Income (Discontinued Operations) | $-3.1M | $-8.3M | $-10.4M | $-12.5M | $-15.6M | $-17.5M | $-23.1M | $-33.6M | $-33.7M | $-40.2M | ||
| Net Income (Common Stockholders) | $-3.1M | $-8.3M | $-10.4M | $-12.5M | $-15.6M | $-17.5M | $-24.5M | $-33.6M | $-33.7M | $-40.2M | ||
| Normalized Income | -- | -- | -- | -- | -- | -- | $-18.2M | -- | -- | $-38.5M | ||
| TOTALS | ||||||||||||
| Total Expenses | $3.5M | $7.4M | $10.0M | $13.7M | $15.6M | $17.7M | $23.5M | $33.3M | $36.7M | $42.0M | ||
| SHARE & EPS DATA | ||||||||||||
| Average Shares Outstanding | $84.9K | $144.9K | $219.3K | $10.7M | $806.5K | $1.6M | $4.3M | $5.8M | $6.1M | $6.7M | ||
| Average Shares Outstanding (Diluted) | $84.9K | $144.9K | $219.3K | $10.7M | $806.5K | $1.6M | -- | $5.8M | $6.1M | $6.7M | ||
| Shares Outstanding | $92.5K | $197.6K | $336.9K | $17.8M | $1.2M | $2.2M | $5.8M | $5.8M | $6.4M | $17.0M | ||
| Basic EPS | $-33.75 | $-56.25 | $-47.25 | $-1.17 | $-19.25 | $-11.25 | $-5.75 | $-5.75 | $-5.5 | $-5.97 | ||
| Basic EPS (Continuing Operations) | $-33.75 | $-56.25 | $-47.25 | $-1.17 | $-19.25 | $-11.25 | $-5.75 | $-5.75 | $-5.5 | $-5.97 | ||
| Diluted EPS | $-33.75 | $-56.25 | $-47.25 | $-1.17 | $-19.25 | $-11.25 | $-5.75 | $-5.75 | $-5.5 | $-5.97 | ||
| Diluted EPS (Continuing Operations) | -- | -- | -- | -- | -- | -- | -- | $-5.75 | $-5.5 | $-5.97 | ||
| OTHER METRICS | ||||||||||||
| Accrued Preferred Stock Dividends | -- | -- | -- | -- | -- | -- | $1.5M | -- | -- | -- | ||
| Earnings from equity interest | -- | -- | -- | -- | -- | $110.2K | -- | -- | -- | -- | ||
| Earnings From Equity Interest Net Of Tax | -- | -- | -- | -- | -- | $110.2K | -- | -- | -- | -- | ||
| Gain On Sale Of Business | $332.1K | -- | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Minority Interests | -- | -- | -- | -- | -- | $33.7M | $132.8M | $103.4M | -- | $287.0K | ||
| Net Income Discontinuous Operations | -- | -- | -- | -- | -- | -- | -- | -- | $3.6M | $2.4M | ||
| Other Gand A | $946.6K | $3.8M | $6.1M | $6.4M | $6.3M | $8.1M | $9.8M | $11.8M | $15.3M | $18.2M | ||
| Otherunder Preferred Stock Dividend | -- | -- | -- | -- | -- | -- | $1.5M | -- | -- | -- | ||
| Preferred Stock Dividends | -- | -- | -- | -- | -- | -- | $1.5M | -- | -- | -- | ||
| Rent And Landing Fees | -- | -- | $26.0K | $6.4M | -- | -- | -- | -- | -- | -- | ||
| Restruct | $6.6M | -- | -- | -- | -- | -- | -- | -- | -- | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | CTXR | $1.58 | +0.6% | 402.32K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Citius Pharmaceuticals Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW